4 Superior Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
It's amazing what a difference a year can make on Wall Street. With the three major stock indexes continuing to oscillate between bear and bull markets in successive years, 2023 turned out to be a phenomenal year for the bulls. Although the Dow Jones Industrial Average powered to a record high, it…#nasdaqcomposite #palantirtechnologies #pltr #palantir #foundry #jdcom #alibaba #hongkong #astrazeneca #oncology (Source: Reuters: Health)
Source: Reuters: Health - January 6, 2024 Category: Consumer Health News Source Type: news
Lab Notes: AstraZeneca enters into another $1B acquisition deal; FDA puts hold on Iovance drug study
Life sciences industry updates include news on a billion-dollar Big Pharma deal, a $4 million stock sale, a cell therapy setback and more. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 2, 2024 Category: Biotechnology Authors: John George Source Type: news
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
NATICK, Mass., Jan. 2, 2024 -- (Healthcare Sales & Marketing Network) -- Allorion Therapeutics ("Allorion"), a US and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune ... Biopharmaceuticals, Oncology, Licensing Allorion Therapeutics, EGFR, non-small cell lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 2, 2024 Category: Pharmaceuticals Source Type: news
India's pharma lobby bats for drug approvals in line with global markets
According to the OPPI, launching a new drug in India is delayed by up to four years, compared to markets like the US and the European Union. This affects the launch of innovative and significant products in India. The lobby represents pharma giants including Novartis, Roche, AstraZeneca, Sanofi and Merck. The group blames the delay on complex clinical trial regulations. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 28, 2023 Category: Pharmaceuticals Source Type: news
The New RSV Drug Keeps Babies Out of the Hospital
Doctors and parents celebrated the major advances that came in 2023 to treat respiratory syncytial virus (RSV), which sends up to 80,000 children under age five to the hospital each year in the U.S. This year, the U.S. Food and Drug Administration approved two critical ways to reduce the risk of RSV in young kids: a vaccine for pregnant mothers that can protect newborns, and a drug treatment for babies under one year.
[time-brightcove not-tgx=”true”]
In a study published in the New England Journal of Medicine, researchers report encouraging real-world data that show how effective the drug treatment, nirsevi...
Source: TIME: Health - December 27, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Source Type: news
Felix Munkonge obituary
My father, Felix Munkonge, who has died aged 64 after a stroke, was a biochemist recognised for the key role he played in coordinating the clinical testing of gene therapy as a potential treatment for cystic fibrosis. He was also a contributor to the team at AstraZeneca that supported the manufacturing capability of the Covid-19 vaccine.Felix joined AstraZeneca as a project manager in November 2020, at the height of the pandemic, and was responsible for managing laboratory-scale collaborations with several chief medical officers around the world. That work made a significant contribution to ensuring the global availability...
Source: Guardian Unlimited Science - December 27, 2023 Category: Science Authors: Mandalena Munkonge Tags: Medical research People in science Zambia Cystic fibrosis AstraZeneca King's College London University of Southampton Biology Source Type: news
AstraZeneca to buy China's Gracell Biotechnologies in $1.2 billion deal
(Source: Reuters: Health)
Source: Reuters: Health - December 27, 2023 Category: Consumer Health News Source Type: news
BMY Stock: Bristol Myers Buying RayzeBio For $4.1 Billion; RYZB Soars
Bristol Myers Squibb (BMY) said Tuesday it would acquire cancer drug developer RayzeBio (RYZB) in a deal valued at $4.1 billion. RYZB stock soared 100% on the news while BMY stock traded slightly lower. Bristol Myers will pay $62.50 per share for RayzeBio, a 104% premium to the company's Friday…#bristolmyerssquibb #bmy #rayzebio #ryzb #bristolmyers #sandiego #samithirawat #astrazeneca #azn #creamofcrop (Source: Reuters: Health)
Source: Reuters: Health - December 27, 2023 Category: Consumer Health News Source Type: news
AstraZeneca to buy China's Gracell Biotechnologies in $1.2 billion deal
(Source: Reuters: Health)
Source: Reuters: Health - December 26, 2023 Category: Consumer Health News Source Type: news
AstraZeneca buys Chinese cancer therapy firm Gracell for $1.2bn
Gracell Biotechnologies acquisition marks China ’s growing importance to the Anglo-Swedish drugmakerAstraZeneca has struck a deal to buy a Chinese cancer therapy company for up to $1.2bn ( £950m), as Britain’s biggest drugmaker expands its footprint in its second-largest market.The Anglo-Swedish pharmaceutical firm announced on Tuesday it would acquire Gracell Biotechnologies, which is focused on a type of cancer therapy known as CAR-T that modifies a patient ’s cells to fight the disease.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - December 26, 2023 Category: Science Authors: Kalyeena Makortoff Tags: AstraZeneca Mergers and acquisitions UK news Business Pharmaceuticals industry Health Medical research Cancer Cancer research China Asia Pacific World news Source Type: news
Why China-Based Gracell Biotechnologies (GRCL) Stock Is Soaring Today
AstraZeneca Plc AZN has agreed to acquire Gracell Biotechnologies Inc GRCL, further strengthening AstraZeneca's cell therapy portfolio. The deal value is $2.00/share (equivalent to $10/ADS ADS of Gracell) plus a non-tradable contingent value right of $0.30/share (equivalent to $1.50/ADS of…#astrazenecaplcazn #astrazeneca #gracell #bcma #susangalbraith (Source: Reuters: Health)
Source: Reuters: Health - December 26, 2023 Category: Consumer Health News Source Type: news
AstraZeneca to Acquire Gracell in $1.2 Billion Deal to Further Cell Therapy Goals
AstraZeneca announced Tuesday it would acquire Gracell Biotechnologies in a deal valued at up to $1.2 billion.#astrazeneca (Source: Reuters: Health)
Source: Reuters: Health - December 26, 2023 Category: Consumer Health News Source Type: news
These Stocks Are Moving the Most Today
Shanghai-based Gracell Biotechnologies is being acquired by AstraZeneca in a deal valued at up to $1.2 billion, a report says Synopsys and Ansys are in merger talks, and British billionaire Jim Ratcliffe agrees to buy a minority stake in Manchester United soccer club.#shanghai #astrazeneca #jimratcliffe #manchesterunited (Source: Reuters: Health)
Source: Reuters: Health - December 26, 2023 Category: Consumer Health News Source Type: news
FDA Approves New Agent for Nerve Pain From Rare Inherited Disease
(MedPage Today) -- Eplontersen (Wainua) was approved by the FDA to treat polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (ATTR) in adults, Ionis Pharmaceuticals and AstraZeneca announced on Thursday.
Hereditary ATTR... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 22, 2023 Category: American Health Source Type: news
Ionis, AstraZeneca get FDA approval for rare genetic disease treatment
Ionis Pharmaceuticals IONS, and AstraZeneca’s AZN, Wainua has been approved by the U.S. Food and Drug Administration for treating a symptom of a rare genetic disease. The FDA approved Wainua, which has generic name eplontersen, for the treatment of the polyneuropathy of hereditary…#astrazenecas #azn #wainua #fda #ionis (Source: Reuters: Health)
Source: Reuters: Health - December 22, 2023 Category: Consumer Health News Source Type: news
